← SynDRA
ENOCITABINE
SynDRA canonical compound SYN0032268 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CMPK1 | POLA1 | POLB | RRM1 | TYMS |
|---|
| Mechanism of action | DNA synthesis inhibitor |
|---|
| Indication | acute myeloid leukemia (AML) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- CMPK1
- POLA1
- POLB
- RRM1
- TYMS
- POLD4
- POLD3
- POLD1
- POLD2
- POLE
- POLA2
- PRIM1
Mechanisms of action (all sources)
- DNA synthesis inhibitor
- Ribonucleotide reductase inhibitor
- POLA1 INHIBITOR
- DNA polymerase (alpha/delta/epsilon) inhibitor
- POLD4 INHIBITOR
- POLD3 INHIBITOR
- POLD1 INHIBITOR
- POLD2 INHIBITOR
- POLE INHIBITOR
- POLA2 INHIBITOR
- PRIM1 INHIBITOR
- PRIM2 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADORA1
- NR3C1
- HRH3
- HTR1A
- HTR2A
- HTR2B
- HTR3A
- KCNH2
- MAOA
- MC3R
- MLNR
- NPY1R
- NR1I2
- OPRD1
- HRH1
- OPRK1
- OPRM1
- PDE3A
- PDE4D
- PGR
- PTGS2
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- TBXA2R
- HRH2
- HDAC6
- ADORA2A
- CCKAR
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
- AGTR1
- AVPR1A
- AVPR2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Nucleic Acid Synthesis Inhibitors
- Anti-Infective Agents
- Antineoplastic Agents
- Antiviral Agents
- Antimetabolites
- Antimetabolites, Antineoplastic
- Immunologic Factors
- Immunosuppressive Agents
- Noxae
- Nucleoside Metabolic Inhibitor
ATC classes
- L01B · ANTIMETABOLITES
- OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- behenoylcytosine arabinoside
- sunrabin
- Enocitabina
- Sunrabin
- NSC-239336
- Sunrabin (TN)
- NSC 239336
- 9YVR68W306
- NCGC00167515-01
- Behenoylcytosine arabinoside
- Enocitabinum
- Enocitabine [INN:JAN]
- BHAC
- Enocitabinum [INN-Latin]
- Enocitabina [INN-Spanish]
- N-(1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)docosanamide
- N(sup 4)-Behenoylcytosine arabinoside
- BRN 0772101
- UNII-9YVR68W306
- N(sup 4)-Behenoyl-1-beta-D-arabinofuranosylcytosine
- Enocitabine (JAN/INN)
- ENOCITABINE [MI]
- ENOCITABINE [INN]
- ENOCITABINE [JAN]
- N(4)-behenoyl-1-beta-arabinofuranosylcytosine
- n4-behenoyl-1-beta-d-arabinofuranosylcytosine
- N-(1-beta-D-Arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)docosanamide
- SCHEMBL7962
- ENOCITABINE [MART.]
- ENOCITABINE [WHO-DD]
- CHEMBL2106589
- DTXSID6046682
- SCHEMBL21051876
- CHEBI:31537
- EX-A2055
- ZINC8214554
- Tox21_112513
- AKOS016014098
Reported adverse events
- Nausea
- Infection
- Sepsis
- Abdominal pain
- Anxiety
- Arrhythmia
- Cardiac arrest
- Chest pain
- Chills
- Constipation
- Cough
- Delirium
Look up ENOCITABINE in the interactive SynDRA portal →